Brain & Behavior Research Foundation 2023 Klerman & Freedman Awards Presentation
Brain & Behavior Research Foundation Honors Innovative Psychiatric Researchers
July 31, 2023 11:50 ET | Brain & Behavior Research Foundation
New York, July 31, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced the winners of its 2023 Klerman and Freedman Prizes, recognizing exceptional clinical...
Magstim LOGO.JPG
Advanced FDA Cleared Magstim Horizon 3.0 Transcranial Magnetic Stimulation Now Available in United Kingdom
July 07, 2023 07:09 ET | Magstim EGI
WHITLAND, United Kingdom, July 07, 2023 (GLOBE NEWSWIRE) -- The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for...
Sandra Sanchez-Roige, Ph.D.
What Genetics is Telling Us About Substance Use Disorders - A Free Webinar from the Brain & Behavior Research Foundation
June 29, 2023 14:55 ET | Brain & Behavior Research Foundation
New York, June 29, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “What Genetics is Telling Us About Substance Use Disorders” on Tuesday,...
NYJD101
Mount Sinai Creates Transformational New Model of Behavioral Health Care With New State-of-the-Art $140 Million Center
June 08, 2023 16:24 ET | Mount Sinai Health System
NEW YORK, June 08, 2023 (GLOBE NEWSWIRE) -- Mount Sinai Health System today hosted a ribbon-cutting ceremony for the newly constructed Mount Sinai-Behavioral Health Center, located at 45 Rivington...
logo-01 (3) copy - Copy2.jpg
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
May 30, 2023 10:00 ET | ConSynance Therapeutics
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
84bd90f5-4a1f-42a8-8eb1-5cb062a0b6ac.png
Schizophrenia Drugs Market Size to Witness Healthy Valuation of US$ 12.6 Billion at 5.6% CAGR by 2032 | Market.us Report
May 25, 2023 07:54 ET | Market.Us
New York, May 25, 2023 (GLOBE NEWSWIRE) -- As per this latest study by Market.us, The global Schizophrenia Drugs Market was valued at US$ 7.4 Bn in 2022. It is projected to expand at a CAGR of 5.6%...
Nexstim’s Quality Sy
Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU
May 17, 2023 07:00 ET | Nexstim Oyj
Press release, Helsinki, 17 May 2023 at 2 PM (EEST) Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received...
Webinar Presenter
How the Brain's Dopamine Circuitry Helps Regulate Cognitive Flexibility and Reward-Seeking
May 02, 2023 12:39 ET | Brain & Behavior Research Foundation
New York, May 02, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “How the Brain's Dopamine Circuitry Helps Regulate Cognitive Flexibility and...
Healthy Minds Two Part Episode on Suicide Prevention
Eighth Season of Healthy Minds with Dr. Jeffrey Borenstein Debuts Nationally During Mental Health Awareness Month in May
April 26, 2023 10:00 ET | Brain & Behavior Research Foundation
New York, April 26, 2023 (GLOBE NEWSWIRE) -- The eighth season of the Emmy® nominated public television series Healthy Minds with Dr. Jeffrey Borenstein debuts nationally in May during Mental Health...
Nexstim Releases NBS
Nexstim Releases NBS 6 in the United States
April 17, 2023 02:00 ET | Nexstim Oyj
Press release, Helsinki, 17 April 2023 at 9 AM (EEST) Nexstim Releases NBS 6 in the United States Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the launch of NBS 6, a new navigated...